news
NICE seeks more information on idelalisib from Gilead
18 June 2015 | By Victoria White
NICE has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig) for adults with chronic lymphocytic leukaemia...
List view / Grid view
Gilead Sciences
news
Idelalisib in combination with ofatumumab improves progression-free survival in previously-treated patients with chronic lymphocytic leukaemia
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
news
EMA validates Marketing Application for fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for HIV treatment
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..
news
Top-line results announced for Phase 2 study of GS-4774 in patients with chronic hepatitis B
28 May 2015 | By Victoria White
Top line results have been announced from the GS-4774 Phase 2 study in patients with HBV on long term viral suppression with an oral antiviral treatment...
news
Harvoni and Sovaldi demonstrate efficacy among chronic hepatitis C patients with advanced liver disease
23 April 2015 | By Victoria White
Results announced from several Phase 2 clinical studies evaluating uses of Harvoni and other Sovaldi-based regimens for the treatment of HCV infection...
news
Gilead submits New Drug Application for F/TAF for the treatment of patients with HIV
8 April 2015 | By Victoria White
Gilead has submitted a NDA to the FDA for an investigational fixed-dose combination of F/TAF for the treatment of HIV-1 infection...
news
Gilead receives approval from the Scottish Medicines Consortium for use of zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia
9 March 2015 | By Gilead Sciences
New oral treatment for Chronic Lymphocytic Leukaemia now approved for use within NHS Scotland...
news
Gilead announces SVR12 rates from Phase 3 study evaluating Harvoni® for the treatment of chronic hepatitis C in patients co-infected with HIV
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
news
Gilead announces Phase 3 results for investigational once-daily single tablet HIV regimen containing tenofovir alafenamide (TAF)
27 February 2015 | By Gilead Sciences
First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...
news
Hepatitis C: Doctors of the World opposes patent for sofosbuvir
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
news
Gielad presents follow-up data from idelalisib (zydelig®) registrational studies in patients with chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
news
Gilead announces Harvoni® (ledipasvir/sofosbuvir) study results in chronic hepatitis C patients with advanced liver disease and those who failed prior treatment
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
news
Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
news
Recent developments keep Gilead ahead of the pack in HIV treatment market, says GlobalData Analyst
8 October 2014 | By GlobalData
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader...
news
European CHMP adopts positive opinion for Gilead’s Harvoni® (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C infection in adults
29 September 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Harvoni®...
